Effect of secretin on portal venous flow

L Bolondi, S Gaiani, S Li Bassi, G Zironi, P Casanova, L Barbara

Abstract
In this study we evaluated the effect of two different doses of secretin on portal haemodynamics (by pulsed Doppler associated with real time ultrasound) in 24 healthy humans. In 12 subjects (group A) we administered an intravenous dose of 75 clinical units of secretin and in the remaining 12 (group B) a dose of 20 CU. In all subjects the following parameters were studied before, during, and for 10 minutes after secretin administration: (a) calibre of the portal vein, (b) mean velocity of portal venous flow, and (c) volume of portal venous flow. In three subjects in each group we also evaluated the changes in flow in the superior mesenteric artery. Secretin injection induced a slight increase in both groups in comparison to basal values of portal vein calibre (mean of maximal per cent increase +25% in group A, not significant, and +16-7% in group B, not significant) and a noticeable increase of mean velocity (mean of maximal per cent increases +61-4% in group A, p<0.005, and +65-4% in group B, p<0.01) and flow volume (mean of maximal per cent increase +127% group A, p<0.005, and +114% group B, p<0.005). The magnitude of the haemodynamic changes did not differ significantly between the two groups. Doppler investigation of the superior mesenteric artery showed a marked increase of flow velocity (mean of maximal per cent increase +218% in group A and +246% in group B) and flow volume (mean of maximal per cent increase +276% in group A and +311% in group B). These data suggest that secretin has an appreciable vasoactive effect and induces a significant increase in portal venous flow even at doses much lower than those necessary for a maximal stimulation of exocrine pancreatic secretion.

Splanchnic hyperaemia due to mesenteric arterial dilatation and increased portal venous flow has been found to occur in normal subjects after a meal. Coupled with observations that many humoral substances are released into the circulation after meals, many hormones, or autacoids, have been proposed as mediators of functional changes in splanchnic haemodynamics. The principal agents that have been assigned a role in the complex regulation of liver blood flow are reported to be: intrinsic hepatic vasoregulation and extrinsic innervation; adrenergic and cholinergic substances; autacoids (bradykinin, serotonin, histamine, prostaglandins) and vasoconstrictor peptides (angiotensins, vasopressin). Data have also been collected regarding the possible role of changes in the composition and osmolarity of portal blood.

Among the gut hormones, glucagon has been shown to induce splanchnic vasodilatation and increased portal venous pressure in dogs in normal humans, and in patients affected by cirrhosis of the liver. Many other substances have shown a vasoactive effect on liver blood flow: synthetic pentagastrin reduces hepatic arterial and portal venous resistance in the dog, and intravenous cholecystokinin increases portal venous blood flow and portal venous pressure without having any effect on hepatic arterial or intrahepatic portal venous vascular resistance. Experimental studies have also shown that intravenous infusion of secretin induces dilatation of mesenteric vasculature and increases portal flow and pancreatic blood flow at pharmacological doses.

In this study we evaluated by means of a duplex Doppler technique the effect on portal venous flow of different doses of intravenous secretin in healthy humans to outline the presence, if any, and the magnitude of the haemodynamic response to the hormone.

Methods

SUBJECTS

A total of 24 normal subjects were entered into this study. Informed consent was obtained in each case. The study was performed in all subjects in a supine position and in the early morning, after overnight fasting, to avoid changes due to posture and the influence of meals on portal haemodynamics. All cases were randomly allocated to two different groups. In 12 subjects (group A: five men and seven women; age range 17–70 years, mean 38-2 years) we administered over one minute an intravenous dose (75 CU) of secretin (Secretolyn, Hoechst) which was proved to induce a maximal stimulation of exocrine pancreatic secretion. In the other 12 subjects (group B: six men and six women; age range 20–57 years, mean 40-5 years) a lower dose (20 CU) was administered intravenously over one minute. For control purposes, in four subjects in each group the investigation was repeated after the intravenous administration (1 min) of corresponding volumes of saline on a different day.

INSTRUMENTATION AND HAEMODYNAMIC PARAMETERS

Real time ultrasound equipment with 3-5 MHz linear, convex, and mechanical sector transducers (Esaote-Hitachi AUC 940 and 450), provided by pulsed Doppler devices operating at a frequency of 3-5 and 2-5 MHz, was used. In all subjects the following parameters were studied immediately before, during, and continuously for 10 minutes after secretin administration: (a) calibre of the portal vein; this was achieved by calculating the anteroposterior diameter (in mm)
during suspended respiration at the largest point where the Doppler signal was obtained; (b) mean velocity (V<sub>mean</sub>) of the portal venous flow (cm/s); (c) volume (F) of the portal venous flow (ml/min).

The same parameters were also evaluated in the superior mesenteric artery in a subgroup of six subjects (three in group A and three in group B) to investigate the eventual effect of secretin on the arterial splanchnic bed. Measurements were taken 3–5 longitudinal superior mesenteric artery diameters, and then the sample volume was positioned at the centre of the vessel. The duplex system allows simultaneous measurement of flow velocity and vessel diameter at the exact point where the sample volume is positioned, avoiding errors due to the discrepancy between the point of Doppler shift registration and vessel measurement. Our equipment displays the angle between the sonic beam and the longitudinal axis of the vessel lumen, and we chose an angle of less than 60 degrees, avoiding larger beam-vessel angles, because of the cosine dependence of velocity measurement error with angle. Flow velocity (V) is directly calculated by the equipment from the Doppler spectral analysis, using the formula:

\[ V = \frac{F d C}{2 F_0 \cos \alpha} \]
as described by Gill, where \( F_0 \) is the Doppler frequency shift, \( C \) the velocity of sound in the tissues (1500 m/s), \( F_0 \) the emitted ultrasonic wave frequency, and \( \alpha \) the angle of incidence between the sonic beam and the longitudinal axis of the vessel. In the present study we measured the 'mean velocity of flow' (V<sub>mean</sub>) in the portal vein and in the superior mesenteric artery. Because flow in a channel structure is laminar—that is, formed by concentric layers of different velocities, increasing from the vessel wall towards the axis—that is the most reliable method for calculating the actual V<sub>mean</sub> by Doppler is the 'even insonation' method. This is achieved by using a sample volume as large as the vessel diameter, taking into account the peripheral component. Our equipment can calculate V<sub>mean</sub> directly from the Doppler spectral analysis. The high-pass filter was kept at its lowest setting (100 Hz). We made V<sub>mean</sub> calculation on Doppler traces of 4–6 s in order to average eventual changes of flow velocity in the portal vein related to cardiac and respiratory cycles, which are also reduced by examining the patients during suspended respiration. In the superior mesenteric artery we considered a trace of three cardiac cycles. Volume (F) of flow in both portal vein and superior mesenteric artery was obtained by this formula: \( F = V_{mean} \cdot \pi r^2 \), where \( r \) represents the half diameter of the vessel.

A videotape recording of the whole study was made in each case to allow careful and complete measurements in patients undergoing evaluation of both portal vein and superior mesenteric artery and to reconsider possible sources of errors in taking measurements. Arterial blood pressure and heart rate (evaluated on electrocardiographic trace) were measured basally and during the whole period of study in each subject.

**STATISTICAL ANALYSIS**

Calibres, V<sub>mean</sub>, and flow of the portal vein and the superior mesenteric artery are presented as mean (SD). One way analysis of variance (ANOVA, Statview Apple Computer Inc) was used to compare values of these parameters at each time interval with basal ones in groups A and B after secretin injection, and in the group injected with saline. Increases in calibre, V<sub>mean</sub>, and flow volumes in the two groups are also expressed as maximal per cent variations over basal values, and were compared between group A and group B by the non-parametric Mann-Whitney U test.

**Results**

Arterial blood pressure and heart rate did not significantly change during the period of study in any of the subjects. No appreciable modification of the calibre and of the haemodynamic profile of the portal vein was observed during and after saline administration. Changes induced by secretin administration are reported separately for each haemodynamic parameter. Results concerning the portal vein are summarised in Tables I and II.

**TABLE I** Maximal increase (expressed as per cent variation) of diameter (D), flow velocity (V<sub>mean</sub>), and flow volume (F) in the portal vein after intravenous injection of 75 CU of secretin (group A)

<table>
<thead>
<tr>
<th>No</th>
<th>Age (years)</th>
<th>Sex</th>
<th>( \theta )</th>
<th>V&lt;sub&gt;mean&lt;/sub&gt;</th>
<th>F</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>17</td>
<td>F</td>
<td>0</td>
<td>27</td>
<td>161</td>
</tr>
<tr>
<td>2</td>
<td>19</td>
<td>F</td>
<td>12</td>
<td>33</td>
<td>70</td>
</tr>
<tr>
<td>3</td>
<td>31</td>
<td>M</td>
<td>38</td>
<td>53</td>
<td>181</td>
</tr>
<tr>
<td>4</td>
<td>24</td>
<td>F</td>
<td>25</td>
<td>100</td>
<td>153</td>
</tr>
<tr>
<td>5</td>
<td>40</td>
<td>F</td>
<td>22</td>
<td>42</td>
<td>53</td>
</tr>
<tr>
<td>6</td>
<td>22</td>
<td>M</td>
<td>43</td>
<td>65</td>
<td>131</td>
</tr>
<tr>
<td>7</td>
<td>70</td>
<td>F</td>
<td>22</td>
<td>47</td>
<td>200</td>
</tr>
<tr>
<td>8</td>
<td>68</td>
<td>F</td>
<td>33</td>
<td>68</td>
<td>131</td>
</tr>
<tr>
<td>9</td>
<td>70</td>
<td>M</td>
<td>10</td>
<td>92</td>
<td>133</td>
</tr>
<tr>
<td>10</td>
<td>43</td>
<td>F</td>
<td>16</td>
<td>90</td>
<td>120</td>
</tr>
<tr>
<td>11</td>
<td>29</td>
<td>M</td>
<td>19</td>
<td>45</td>
<td>100</td>
</tr>
<tr>
<td>12</td>
<td>36</td>
<td>M</td>
<td>25</td>
<td>75</td>
<td>78</td>
</tr>
<tr>
<td>Mean</td>
<td>38.2</td>
<td></td>
<td>25</td>
<td>61.4</td>
<td>127.6</td>
</tr>
</tbody>
</table>

**TABLE II** Maximal increase (expressed as per cent variation) of calibre (D), flow velocity (V<sub>mean</sub>), and flow volume (F) in the portal vein after intravenous injection of 20 CU of secretin (group B)

<table>
<thead>
<tr>
<th>No</th>
<th>Age (years)</th>
<th>Sex</th>
<th>( \theta )</th>
<th>V&lt;sub&gt;mean&lt;/sub&gt;</th>
<th>F</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>42</td>
<td>M</td>
<td>9</td>
<td>88</td>
<td>93</td>
</tr>
<tr>
<td>2</td>
<td>48</td>
<td>M</td>
<td>22</td>
<td>88</td>
<td>180</td>
</tr>
<tr>
<td>3</td>
<td>57</td>
<td>F</td>
<td>11</td>
<td>88</td>
<td>93</td>
</tr>
<tr>
<td>4</td>
<td>61</td>
<td>F</td>
<td>9</td>
<td>47</td>
<td>61</td>
</tr>
<tr>
<td>5</td>
<td>43</td>
<td>F</td>
<td>11</td>
<td>88</td>
<td>131</td>
</tr>
<tr>
<td>6</td>
<td>30</td>
<td>F</td>
<td>30</td>
<td>68</td>
<td>184</td>
</tr>
<tr>
<td>7</td>
<td>28</td>
<td>F</td>
<td>22</td>
<td>64</td>
<td>98</td>
</tr>
<tr>
<td>8</td>
<td>20</td>
<td>M</td>
<td>17</td>
<td>94</td>
<td>124</td>
</tr>
<tr>
<td>9</td>
<td>30</td>
<td>M</td>
<td>20</td>
<td>35</td>
<td>94</td>
</tr>
<tr>
<td>10</td>
<td>32</td>
<td>F</td>
<td>18</td>
<td>42</td>
<td>102</td>
</tr>
<tr>
<td>11</td>
<td>46</td>
<td>M</td>
<td>15</td>
<td>61</td>
<td>120</td>
</tr>
<tr>
<td>12</td>
<td>29</td>
<td>M</td>
<td>21</td>
<td>50</td>
<td>90</td>
</tr>
<tr>
<td>Mean</td>
<td>40.5</td>
<td></td>
<td>16.7</td>
<td>65.4</td>
<td>114</td>
</tr>
</tbody>
</table>
cases the maximum calibre increase was observed after 2 min (mean (SD) 11·5 (3·2) mm, not significant, in group A; 11·2 (1·5) mm, not significant, in group B). The mean per cent calibre increase was 25% in group A and 16·7% in group B (Tables I and II). After 4 min a progressive calibre decrease occurred and after 7 min (group B) and 8 min (group A) the calibre was again within basal values. In the subjects in which the superior mesenteric artery was studied basal values were 4·6 (0·6) mm in group A and 4·9 (0·3) mm in group B. The mean calibre varied after secretin administration with a maximal increase at the second min (5·1 (0·8) mm in group A, not significant; 5·4 (0·5) mm in group B, not significant). The mean per cent increase (8·5% in group A and 8·1% in group B) was not consistently different in the two groups.

VELOCITY OF FLOW
Basal values of $V_{\text{mean}}$ in the portal vein were 19·1 (5·7) cm/s in group A and 16·3 (3·1) cm/s in group B. Figure 2 shows changes of $V_{\text{mean}}$ in groups A and B, expressed as mean (SD). The maximal increase in $V_{\text{mean}}$ was reached 2 min after the start of secretin administration (Fig 3) (31·3 (5·2)/cm/s, $p<0.005$, in group A; 26·7 (6·3)/cm/s, $p<0.01$, in group B). At the end of the study $V_{\text{mean}}$ returned to within basal values in 11 out of 12 subjects in both groups. The maximal increases of flow velocities, calculated as mean per cent variation over basal values, shown in Tables I and II, ranged from 27% to 100% in group A (mean=61·4) and from 35% to 94% in group B (mean=65·4). The mean per cent increase did not significantly differ between the two groups.

In the subjects in which superior mesenteric artery was studied, basal values of $V_{\text{mean}}$ were 22·7 (4·2) cm/s in group A and 21·7 (3·1) cm/s in group B. At 2 min $V_{\text{mean}}$ was raised to 76·7 (4) in group A ($p<0.05$) and 67·7 (3·6) in group B ($p<0.05$). The mean per cent increase (246% in group A and 218% in group B) was not consistently different in the two groups.

FLOW VOLUME
Basal values of flow in the portal vein were 782 (353) ml/min in group A and 727 (212) ml/min in group B. Figure 4 shows the noticeable increase of flow after both 75 CU and 20 CU of secretin. Maximal values (1957 (921) ml/min, $p<0.005$, in group A, and 1579 (575) ml/min, $p<0.005$, in group B) corresponded to the maximal increase of calibre and $V_{\text{mean}}$ and were reached between one and two minutes (Fig 5). The increase of flow varied among the subjects examined: Tables I and II show these changes reported as per cent variation in comparison with basal values. In most cases it was well over 90% in both group A (127-6%) and group B (114%) with no significant difference between the two groups.

In the subjects in which superior mesenteric artery was studied basal values of flow were 227 (29) ml/min in group A and 252 (49) ml/min in group B. Maximal mean values were 937 (271)
ml/min in group A (p<0.05) and 926 (206) ml/min in group B (p<0.05). The mean per cent increase (311% in group A and 276% in group B) was not consistently different in the two groups.

Discussion

Most studies on nervous and hormonal regulation of blood flow in the liver have been made using isolated hepatic perfusion systems in anaesthetised animals. Apart from the possible effects of total anaesthesia on liver blood flow and differences between animals and humans, it is often difficult to compare results obtained from different laboratories due to differences in experimental techniques.1

Duplex Doppler ultrasound is actually the only method which allows a non-invasive and dynamic visualisation of the portal vein together with the evaluation of haemodynamic parameters. The quantitative assessment of blood velocity and flow by Doppler method in the portal vein20-22 and in the superior mesenteric artery has been reported in previous studies.23-25 Possible sources of errors with this method were outlined in a cautionary review by Gill et al26 and reconsidered by Burns and coworkers27 and Dauzat and Pomier Layrargues.28 They include the measurement of cross sectional area of the vessel and the angle of approach. Errors in measuring cross sectional area may affect calculation of flow volumes but not Vmean. It is, however, accepted that repeated measurements of the diameters reduce the error of flow calculation to within 10%.29 Furthermore, it has been shown recently that variations in the cross diameter of the portal vein are not significantly related to flow measurement errors. The angle of approach, if larger than 60°, may appreciably affect the calculation of flow velocity owing to the dependence of the cosine of the angle of velocity measurement. This study was performed only on subjects where it was possible to use angles below 60° (usually from 30° to 50°).

In these cases an uncertainty of 5° (which is difficult to reach in our opinion) results in an error of flow velocity ranging from 5 to 10%. The filter of 100 Hz used may also eliminate low velocity signals (usually under 4 cm/s when the angle of approach is below 60°). This means that the possible overestimation of Vmean in basal conditions may result in a lower difference with values measured after secretin administration. Therefore the validity of our results is not affected.

Measurements of changes of flow velocity and volume in the same subject under different conditions are even more acceptable, since any potential experimental errors should be a constant in a subject both before and after drug administration. Duplex Doppler seems therefore to be a suitable method for in vivo monitoring of acute haemodynamic changes induced by hormones, drugs, and other substances on portal blood flow.18 20

Using this technique we have shown that an intravenous bolus of secretin induces an impressive increase of portal flow velocity and volume in humans. These findings are in agreement with previous experimental reports showing dilatation of mesenteric vasculature and increased portal venous blood flow after intra-arterial injection of this hormone.11

Similar results have also been reported in humans by Okazaki et al3 using a maximal dose (1 U/kg) of secretin. We found that the response of portal flow to secretin stimulation is early (within 2 min) and in some cases an appreciable effect was noted just before the end of the bolus injection. This behaviour is closely similar to the response of the main pancreatic duct to secretin stimulation34 and may suggest a direct effect of the hormone on splanchnic vasculature. The pronounced increase of superior mesenteric arterial flow observed in the six cases examined indicates a direct effect of secretin on arterial splanchnic bed and suggests that secretin modulates portal flow indirectly by changing mesenteric arterial inflow rather than directly affecting portal vascular tone. We cannot, however, exclude the role of reduced portal and intrahepatic resistance, as was reported to occur in experimental studies on isolated portal vein.31

The disappearance of the effect of secretin six to eight minutes after the beginning of the injection is related to its short plasma half life, which is about two to four minutes.34 35
Glucagon, a polypeptide with structural similarity to secretin, shares a common amino acid sequence. It has been used to induce splanchic vasodilation and increase portal venous pressure. The basis of experimental studies of this effect seems to be a result of an increase in both inflow volume and intrahepatic portal resistance. It is unlikely that this hormone has a physiological role in postprandial hyperaemia since the release of glucagon depends mainly on a substantial drop in plasma glucose concentrations, and a glucagon containing meal causes a decrease rather than an increase of serum glucagon. It has been suggested that cholecystokinin, which increases portal venous blood flow and portal venous pressure in dogs, is the most likely candidate for increasing intestinal blood flow in the postprandial state.

Secretin may add to the known effect of cholecystokinin on postprandial blood flow in a similar way to their combined effect on pancreatic exocrine function.

As far as this problem is concerned the final question is to establish if the observed effect of secretin on portal flow is only pharmacological or even physiological. The significant increase of portal vein and superior mesenteric arterial flow observed after the lower dose of secretin (20 CU), which corresponds to less than one third of the dose used to stimulate the maximal exocrine pancreatic secretion, shows a high sensitivity of the splanchic vascular bed to secretin stimulation. This might suggest a role for secretin in the modulation of postprandial splanchic hyperaemia. This point cannot, however, be established from our data and further investigation is needed to confirm this hypothesis.

Effect of secretin on portal venous flow.

L Bolondi, S Gaiani, S Li Bassi, G Zironi, P Casanova and L Barbara

*Gut* 1990 31: 1306-1310
doi: 10.1136/gut.31.11.1306